Latest News

Noah G. Banoub discusses a study finding MacTel2 misdiagnosed in 25.5% of cases, common mimics, misleading imaging, and Encelto's approval.

Phase 3 DURAVYU insert misses key vision endpoint in wet AMD but cuts injections; pivotal LUCIA readout may decide its future.

Byron Lam, MD, and Benjamin Bakall, MD, PhD, discuss what an FDA approval of tinlarebant could mean for the Stargardt disease type 1 standard of care.

EyePoint has finished enrolling both pivotal Phase 3 trials evaluating its sustained-release intravitreal insert against aflibercept in diabetic macular edema, setting up a topline readout in late 2027.

Margaret A. Chang, MD, MS, on MK-8748's dual Tie2/VEGF mechanism, what MALBEC's data must show to shift wet AMD care, and where DME and RVO fit next.

Wnt modulators, sustained-release TKIs, and topical steroids are in phase 3 trials for DME, offering alternatives to anti-VEGF injections.

FDA grants priority review to Belite Bio's tinlarebant NDA for Stargardt disease type 1, setting a February 2027 PDUFA date for a potential first STGD1 therapy.

Gene therapies, Tie2 agonism, and new delivery platforms are advancing through phase 3 trials in wet and dry AMD, testing mechanisms distinct from anti-VEGF and complement inhibition.

Bakall on 3-year REMAIN data for MCO-010 in retinitis pigmentosa: durable 3-line acuity gains, why genotype did not matter, and which patients responded best.

Barakat, MD, FASRS, on recognizing neovascular conversion in macular telangiectasia type 2, distinguishing it from neovascular AMD on imaging, and treating it without a robust evidence base.

The FDA has cleared an IND for RAG-1C, a first-in-class saRNA therapy targeting proliferative vitreoretinopathy.

Seven-year Vestrum data: anti-VEGF gaps hit 40% of patients with wet AMD by year 1, worsening vision.

In this Q&A, Vance Thompson, MD, clears up myths about dry eye and LASIK wearing off, and explains how better screening and technology are making the procedure more precise for younger patients.